Multi-Ingredient Supplement V14 Slows Age-Related Mobility Decline in Worms
A C. elegans study finds V14™ outperforms AG1® in preserving movement with age, with transcriptomics revealing metabolic and stress-response pathway shifts.
Summary
Researchers tested two popular multi-ingredient nutritional supplements — V14™ and AG1® — on the roundworm C. elegans, a standard model for aging research. Using automated imaging technology, they tracked worm movement and speed over time as proxies for healthspan. Worms given V14™ maintained significantly better mobility with age compared to those receiving AG1® or a control. V14™ contains over 40 ingredients including NAD+ precursors, resveratrol, taurine, pterostilbene, and bioflavonoids. Gene expression analysis revealed V14™ modulated metabolism and stress-response pathways linked to aging. While promising, the findings are in worms, not humans, and the study was partly funded by the maker of V14™, introducing potential bias.
Detailed Summary
Extending healthspan — the years spent in active good health — rather than simply lifespan is increasingly the central goal of longevity research. Nutritional supplements represent one of the most accessible interventions, yet human trials take years and require enormous sample sizes. Researchers turned to C. elegans, a tiny roundworm that ages within weeks, to rapidly screen two commercially available multi-ingredient supplements for their effects on age-related physical decline.
The study compared V14™ (40+ ingredients including dihydronicotinamide mononucleotide, trans-resveratrol, taurine, and pterostilbene) against AG1® (70+ ingredients plus five probiotic strains) and a solvent control. Worm mobility — a validated proxy for healthspan in this organism — was tracked longitudinally using WormGazer™ automated imaging, capturing movement frequency and speed over the animals' lifespan.
Worms exposed to V14™ showed meaningfully greater movement and faster speeds as they aged compared to both AG1® and the control group. To probe the mechanisms, the team performed transcriptomic profiling on V14™-treated worms, revealing modulation of metabolic and stress-response pathways — biological processes closely tied to aging across species. AG1®, despite containing more total ingredients, did not demonstrate the same mobility benefits.
These findings suggest that ingredient composition and synergy matter more than sheer ingredient count when designing longevity-oriented supplements. The identification of affected gene expression pathways offers a mechanistic foothold for future research in more complex organisms and, eventually, humans.
Caveats are significant. C. elegans lacks many mammalian physiological systems, so translation to human benefit is speculative. The study was supported by Youth and Earth, the company that manufactures V14™, and one author is its founder — a meaningful conflict of interest. Only the abstract was available for this summary, limiting full methodological assessment.
Key Findings
- V14™ improved worm movement speed and frequency with age versus both AG1® and solvent control.
- V14™ transcriptomics revealed upregulated metabolic and stress-response pathways associated with aging.
- AG1®, despite having more ingredients and added probiotics, showed no significant mobility advantage.
- NAD+ precursors, resveratrol, taurine, and pterostilbene are likely key active components in V14™.
- Ingredient synergy, not ingredient count, appears critical for healthspan-relevant supplement effects.
Methodology
C. elegans worms were exposed to V14™, AG1®, or a solvent control and tracked longitudinally using WormGazer™ automated imaging for movement speed and frequency. Transcriptomic profiling was conducted on V14™-treated worms to identify gene expression changes. Study design was observational within a model organism framework; no lifespan data were reported in the abstract.
Study Limitations
C. elegans is a simple invertebrate model and findings may not translate to mammals or humans. The study carries a significant conflict of interest — it was funded by the manufacturer of V14™, and one co-author is the company's founder. This summary is based on the abstract only, so full methodology, effect sizes, and statistical details could not be assessed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: